Humera Chowdhary
Child & Adolescent Psychiatry · Denton, TXNPI 1528262714
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,942 of the $3,078 with a category attached, or 63.1%. 15 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 43.9% of the total. Reporting peaked in 2024 at $1,490 and has fallen 62.0% since, to $566 in 2025.
Across 49 payments — averaging $62.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Neuronetics, Inc.$372
- Johnson & Johnson$257
- Janssen Scientific Affairs, LLC$200
- Otsuka America Pharmaceutical, Inc.$187
- Axsome Therapeutics, Inc.$176
- plus $535 from 9 others
Across 62 payments — averaging $1917.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$58K
- Alkermes, Inc.$39K
- Eli Lilly$15K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
What the payments were for
- Consulting fees$2006%
- Travel & lodging$93530%
- Food & beverage$1,94263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 12 | $1,352 |
| Neuronetics, Inc. | 9 | $372 |
| Johnson & Johnson | 3 | $257 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Otsuka America Pharmaceutical, Inc. | 4 | $187 |
| Axsome Therapeutics, Inc. | 3 | $176 |
| Alkermes, Inc. | 3 | $159 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $144 |
| AbbVie(2 entities) | 5 | $96 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Neurocrine Biosciences, Inc. | 1 | $30 |
| Tris Pharma Inc | 1 | $21 |
| Livanova USA, Inc. | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,078 in reported general payments places this provider in the 85th percentile of 301 child & adolescent psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ziprasidone Hcl | 26 | $1,126 |
| Quetiapine Fumarate | 16 | $524 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $296 |
| Trazodone Hcl | 13 | $256 |
| Zolpidem Tartrate | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Denton
- Alain KaticBellaire$106K
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- John SteffekSpring$14K
- Robert MosquedaEdinburg$13K
- Gloria BrunGreenville$10K
- Mudassar TariqSugar Land$9K
- Charles PryzantDallas$9K
- Mehvesh AfrinaPlano$8K
- Kishore SunkaraHurst$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.